EARNEST Partners’s Moderna MRNA Stock Holding History

EARNEST Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-161	Closed	-$16.6K	–	791
2023 Q3	$16.6K	Hold	161	–	–	﹤0.01%	533
2023 Q2	$19.6K	Hold	161	–	–	﹤0.01%	487
2023 Q1	$24.7K	Hold	161	–	–	﹤0.01%	436
2022 Q4	$28.9K	Hold	161	–	–	﹤0.01%	410
2022 Q3	$19K	Hold	161	–	–	﹤0.01%	466
2022 Q2	$23K	Hold	161	–	–	﹤0.01%	435
2022 Q1	$28K	Hold	161	–	–	﹤0.01%	422
2021 Q4	$41K	Buy	161 +43	+36%	+$12.6K	﹤0.01%	363
2021 Q3	$45K	Hold	118	–	–	﹤0.01%	345
2021 Q2	$28K	Hold	118	–	–	﹤0.01%	415
2021 Q1	$15K	Hold	118	–	–	﹤0.01%	532
2020 Q4	$12K	Hold	118	–	–	﹤0.01%	573
2020 Q3	$8K	Hold	118	–	–	﹤0.01%	629
2020 Q2	$8K	Buy	+118	New	+$6.46K	﹤0.01%	618

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EARNEST Partners's MRNA Position: Q4 2023 in Review

EARNEST Partners sold out of Moderna (MRNA) in Q4 2023, closing a stake of 161 shares — an estimated $16.6K sold.

EARNEST Partners first reported a position in MRNA in Q2 2020 and held it in 14 quarters. The position peaked at $45K in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

EARNEST Partners reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 161 Moderna shares in Q4 2023, an estimated $16.6K.
EARNEST Partners first reported a position in Moderna in Q2 2020 and held it in 14 quarters.
EARNEST Partners's Moderna position peaked at $45K in Q3 2021.
884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.